Background: United Kingdom guidelines for the use of biologic disease modifying anti-rheumatic drugs (bDMARDS) for rheumatoid arthritis (RA) require patients to have active disease (Disease Activity Score [DAS28] >5.1) and have failed ≥2 previous conventional synthetic DMARDs (csDMARD). Patients with moderate disease activity (MDA) do not meet these criteria, yet often have poor outcomes. This study aimed to identify trajectory groups of disability scores over three years in RA patients with MDA. Methods: The study included biologic-naïve patients receiving csDMARDs only with MDA (3.2 <DAS28≤ 5.1) when recruited to the control cohort of the British Society for Rheumatology Biologics Register–RA (BSRBR-RA). Disability scores, measured usi...
Objectives: Biologic disease-modifying antirheumatic drugs (bDMARDs) have revolutionised treatment a...
International audienceINTRODUCTION: The aim of this study was to determine a low disease activity th...
International audienceINTRODUCTION: The aim of this study was to determine a low disease activity th...
BACKGROUND: United Kingdom guidelines for the use of biologic disease modifying anti-rheumatic drugs...
BackgroundUnited Kingdom guidelines for the use of biologic disease modifying anti-rheumatic drugs (...
BackgroundUnited Kingdom guidelines for the use of biologic disease modifying anti-rheumatic drugs (...
Background Response to disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) i...
AbstractBackgroundResponse to disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis...
Objective: The aim was to study the course of disease activity and disability in early rheumatoid a...
Objective The Health Assessment Questionnaire is widely used for patients with inflammatory polya...
AbstractObjectiveThe Health Assessment Questionnaire is widely used for patients with inflammatory p...
Objectives: To examine the association between disease activity in early rheumatoid arthritis (RA), ...
OBJECTIVES To analyse the trajectories of Disease Activity Score 28 (DAS28), patient global assessm...
Background: Response to disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) ...
BACKGROUND: We examined models to predict disease activity transitions from moderate to low or sever...
Objectives: Biologic disease-modifying antirheumatic drugs (bDMARDs) have revolutionised treatment a...
International audienceINTRODUCTION: The aim of this study was to determine a low disease activity th...
International audienceINTRODUCTION: The aim of this study was to determine a low disease activity th...
BACKGROUND: United Kingdom guidelines for the use of biologic disease modifying anti-rheumatic drugs...
BackgroundUnited Kingdom guidelines for the use of biologic disease modifying anti-rheumatic drugs (...
BackgroundUnited Kingdom guidelines for the use of biologic disease modifying anti-rheumatic drugs (...
Background Response to disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) i...
AbstractBackgroundResponse to disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis...
Objective: The aim was to study the course of disease activity and disability in early rheumatoid a...
Objective The Health Assessment Questionnaire is widely used for patients with inflammatory polya...
AbstractObjectiveThe Health Assessment Questionnaire is widely used for patients with inflammatory p...
Objectives: To examine the association between disease activity in early rheumatoid arthritis (RA), ...
OBJECTIVES To analyse the trajectories of Disease Activity Score 28 (DAS28), patient global assessm...
Background: Response to disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) ...
BACKGROUND: We examined models to predict disease activity transitions from moderate to low or sever...
Objectives: Biologic disease-modifying antirheumatic drugs (bDMARDs) have revolutionised treatment a...
International audienceINTRODUCTION: The aim of this study was to determine a low disease activity th...
International audienceINTRODUCTION: The aim of this study was to determine a low disease activity th...